LimFlow Announces Agreement To Be Acquired by Inari Medical; LimFlow Will Receive $250M In Cash At Closing And Be Eligible To Receive Up To $165M In Additional Payments Based On Certain Commercial And Reimbursement Milestones Total Value Of $415M
Portfolio Pulse from Benzinga Newsdesk
Inari Medical (NASDAQ:NARI) has agreed to acquire LimFlow SA, a developer of minimally-invasive technology for the treatment of chronic limb-threatening ischemia. The deal is worth up to $415 million, with $250 million in cash at closing and up to $165 million in additional payments based on certain milestones. The transaction is expected to close in Q4 2023. The acquisition is expected to increase patient access to LimFlow's FDA-approved system for Transcatheter Arterialization of the Deep Veins.
November 01, 2023 | 9:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inari Medical's acquisition of LimFlow could potentially expand its product portfolio and increase patient access to LimFlow's FDA-approved system. This could potentially drive growth for Inari Medical.
The acquisition of LimFlow by Inari Medical is expected to increase patient access to LimFlow's system, which could potentially drive growth for Inari Medical. Furthermore, the acquisition aligns with Inari's mission to address significant unmet patient needs, which could potentially enhance its market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100